Type 2 Diabetes

Type 2 diabetes, formerly called adult-onset or noninsulindependent diabetes, is the most common form of diabetes. People can develop type 2 diabetes at any age, even during childhood. This form of diabetes usually begins with insulin resistance, a condition in which fat, muscle, and liver cells do not use insulin properly. At first, the pancreas keeps up with the added demand by producing more insulin. In time, however, it loses the ability to secrete enough insulin in response to meals. People who are overweight and inactive are more likely to develop type 2 diabetes. Treatment includes taking diabetes medicines, making wise food choices, exercising regularly, controlling blood pressure and cholesterol, and taking aspirin daily—for some.

What is Type 2 Diabetes?

Type 2 diabetes is a common metabolic condition that develops when the body fails to produce enough insulin or when insulin fails to work properly, which is referred to as insulin resistance. Insulin is the hormone that stimulates cells to uptake glucose from the blood to use for energy.

Diabetes Mellitus Type 2 Pathophysiology

Type 2 Diabetes Symptoms

Type 2 Diabetes Diagnosis

Type 2 Diabetes Screening and Prevention

Type 2 Diabetes Treatment

Living With Type 2 Diabetes

Vitamin D and Type 2 Diabetes

Is a Plant-Based Diet Good for Type 2 Diabetes?

Are Low Carbohydrate Diets Good for Type 2 Diabetes?

What is Insulin Resistance?

Insulin Resistance Pathophysiology

See more featured articles »

Causes of Insulin Resistance

Insulin Resistance Treatment

Insulin Resistance Diagnosis

Insulin Resistance Symptoms

Insulin Resistance and Parkinson's Disease

Does the Keto Diet Increase the Risk of Diabetes?

The Risks of Prediabetes

What is Diabetes?

Fibromyalgia and Diabetes

Diabetes in Men versus Women

Insulin Medication

Latest Type 2 Diabetes News and Research

Are your ‘takeaway’ coffees exceeding daily recommended levels for caffeine intake?

The caffeine content in various popular coffee servings to assess their safety regarding recommended daily intake limits.

26 Jul 2024

New review highlights advances in diabetes research and treatment

A new paper surveying advances in diabetes pathogenesis and treatment explores the complex factors contributing to the onset and progression of the disease, suggesting that an understanding of these dynamics is key to developing targeted interventions to reduce the risk of developing diabetes and managing its complications.

25 Jul 2024

Could a Mediterranean diet be the secret to avoiding gestational diabetes?

The Mediterranean diet significantly reduces the risk of gestational diabetes mellitus (GDM) according to a new systematic review and meta-analysis. Higher adherence to this diet correlates with lower GDM incidence.

25 Jul 2024

Study reveals moderate burden of post-COVID conditions in primary care

The post-COVID-19 conditions (PCC) or long COVID prevalence among United States (US) adults infected with SARS-CoV-2.

25 Jul 2024

Boosting ketone levels enhances heart function in mice with HFpEF, study shows

Increasing ketone supply to the heart in mice with heart failure with preserved ejection fraction (HFpEF) allowed their hearts to utilize more ketones and produce more energy, according to preliminary research presented today at the American Heart Association's Basic Cardiovascular Sciences Scientific Sessions 2024.

24 Jul 2024

Financial incentives boost meal replacement therapy success in severely obese adolescents

Adolescents with severe obesity who received meal-replacement therapy plus financial incentives experienced a greater reduction in body mass index compared to those who received meal replacement therapy alone, according to recent findings published in JAMA Pediatrics.

23 Jul 2024

Study investigates the link between an exposome score and metabolic health across childhood

The combined effect of environmental exposures and unhealthy lifestyle habits can affect children's cardiometabolic health in a way that exceeds their separate effects.

23 Jul 2024

Beyond the anti-obesity benefits of glucagon-like peptide-1 drugs

The advantages of glucagon-like peptide-1 (GLP-1) medicines beyond glycemic and weight control.

23 Jul 2024

Study identifies trends in the use of glucagon-like peptide-1 receptor agonists

Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs)-;prescription medications sold under popular drug names like Ozempic and Wegovy-;in the United States.

22 Jul 2024

Long-term sulfonylurea use linked to increased risk of hypoglycemia unawareness

Sulfonylureas are a class of oral medications used to manage blood glucose levels in patients with type 2 diabetes.

22 Jul 2024

Exploring the expanding horizons of GLP-1 therapies beyond diabetes and obesity

In a Perspective, Daniel Drucker highlights the growing body of evidence that hints at the potential of glucagon-like peptide-1 (GLP-1)-based medications in treating conditions other than diabetes and obesity, including cardiovascular disease and neurodegenerative disorders.

18 Jul 2024

Unhealthy sleep patterns associated with Type 2 diabetes risk in racially and economically diverse adults

Persistently unhealthy sleep, either not enough or too much, is associated with a significantly increased risk of Type 2 diabetes in a racially and economically diverse adult population, an international team of researchers has reported.

18 Jul 2024

Exploring the impact of eating timing on health and metabolism

Accumulating evidence on the effect of the time of eating in relation to our circadian rhythm and metabolism shows that when we eat may influence our overall health and well-being.

18 Jul 2024

Feline gut microbes shed light on obesity treatment for humans

Pet cats may be excellent animal models for the study of obesity origins and treatment in humans, a new study of feline gut microbes suggests – and both species would likely get healthier in the research process, scientists say.

18 Jul 2024

New four-year initiative targets cardiovascular-kidney-metabolic syndrome

About 1 in 3 U.S. adults have at least three risk factors for cardiovascular-kidney-metabolic (CKM) syndrome, a health disorder related to the strong connections among cardiovascular disease, kidney disease and metabolic disease (such as Type 2 diabetes and obesity).

18 Jul 2024